New drug SRN001 takes first step toward fighting lung scarring
NCT ID NCT07407543
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests the safety and tolerability of an investigational drug called SRN001 in 30 healthy Korean and Caucasian men. Participants receive either SRN001 or a placebo to see how the drug moves through the body and whether it causes side effects. The goal is to gather early safety data that could support future studies in people with idiopathic pulmonary fibrosis, a serious lung-scarring disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SRN001
What this could lead to
If this early trial shows SRN001 is safe, it could pave the way for future studies testing it as a treatment for idiopathic pulmonary fibrosis.
What could go wrong
This is a very early Phase 1 trial in only 30 healthy volunteers, not patients with the disease. It is designed to check safety, not effectiveness, so there is no guarantee SRN001 will work for pulmonary fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••